TY  - JOUR
TI  - Biologic Therapy Carries a Very Low Risk of Reactivation in Hepatitis B Surface Antigen-Negative Phase of Hepatitis B
AB  - Background: The risk of hepatitis B reactivation in hepatitis B surface antigen-negative phase of hepatitis B virus-infected patients exposed to biologic agents is not clear. We aimed to investigate the reactivation rate in hepatitis B surface antigen-negative phase of hepatitis B virus-infected patients after biologic therapy. Methods: Patients followed at gastroenterology, rheumatology, and dermatology clinics with a diagnosis of immune-mediated inflam- matory diseases were screened. Immune-mediated inflammatory diseases patients exposed to biologic agents with a negative hepatitis B surface antigen and positive hepatitis B core immunoglobulin G antibody were included in the study. Results: We screened 8266 immune-mediated inflammatory disease patients, and 2484 patients were identified as exposed to biologic agents. Two hundred twenty-one patients were included in the study. The mean age was 54.08 ± 11.69 years, and 115 (52.0%) patients were female. The median number of different biologic subtype use was 1 (range: 1-6). The mean biologic agent exposure time was 55 (range: 2-179) months. One hundred and fifty-two (68.8%) patients used a concomitant immunomodulatory agent, and 84 (38.0%) patients were exposed to corticosteroids during biologic use. No hepatitis B reactivation with a reverse seroconversion of hepatitis B surface antigen positivity was seen. Antiviral prophylaxis for hepatitis B was applied to 48 (21.7%) patients. Hepatitis B virus-DNA was screened in 56 (25.3%) patients prior to the biologic exposure. Two patients without antiviral prophylaxis had hepatitis B virus-DNA reactivation with a negative hepatitis B surface antigen during exposure to the biologic agent. Conclusion: We found 2 reactivations and no hepatitis B surface antigen seroconversion in our cohort. Antiviral prophylaxis for patients exposed to biologic agents may need to be discussed in more detail.
AU  - Ergun, Tulin
AU  - ergenç, ilkay
AU  - Kani, Haluk Tarik
AU  - aslan, rahmi
AU  - alahdab, yesim
AU  - Inanc, Nevsun
AU  - ATAGUNDUZ, MEHMET PAMIR
AU  - Direskeneli, Haner
AU  - Sevik, Gizem
AU  - Seckin Gencosmanoglu, Dilek
AU  - Cömert Özer, Elif
AU  - ALIBAZ-ONER, FATMA
AU  - Karabacak, Murat
AU  - Mehdiyev, Shahin
AU  - Jafarov, Fuad
AU  - Abacar, Kerem Yiğit
AU  - Kutlug agackiran, Seda
AU  - ATUG, OZLEN
DO  - 10.5152/tjg.2022.22196
PY  - 2023
JO  - Turkish Journal of Gastroenterology
VL  - 34
IS  - 2
SN  - 1300-4948
SP  - 73
EP  - 77
DB  - TRDizin
UR  - http://search/yayin/detay/1173588
ER  -